Slide 1

Slide 2 Arizona, USA 2011 MFMER | 3133089-1 Ruben A. Mesa, MD Professor & Chairman, Division of Hematology & Medical Oncology Deputy Director, Mayo Clinic Cancer Center Mayo Clinic Arizona, USA What should you expect of your MPN Therapy? Slide 3 2011 MFMER | 3133089-2 What should you expect of your MPN Therapy? Individualizing Therapy What is the spectrum of disease burden and risk in MPNs? What are expectations of therapy? Current and evolving treatment options for MPN patients Slide 4 Burden of ET/PV Microvascular Symptoms Microvascular Symptoms Macrovascular Risk MPN Associate d Symptom s Burden of Myelofibrosis Anemia/ Cytopenis Anemia/ Cytopenis Splenomegaly MF Associated Symptoms Et & PV Associated Symptoms Slide 5 Evolution of MPN Symptom Assessment Tools MFSAF 2009 (19 items) MF-SAF 2.0 (7 items 2011) JCO in Press MFSAF 2009 (19 items) MF-SAF 2.0 (7 items 2011) JCO in Press Brief Fatigue Inventory (BFI) 9 Items Brief Fatigue Inventory (BFI) 9 Items Spleen Sx 4 Items Spleen Sx 4 Items Constitutional Sx 5 Items Constitutional Sx 5 Items QOL 1 Item Vascular and Sx 9 Items Vascular and Sx 9 Items MPNSAF 2011 (27 items) Blood 2011 MPN-SAF TSS (10 items 2012) JCO 2012 MPNSAF 2011 (27 items) Blood 2011 MPN-SAF TSS (10 items 2012) JCO 2012 MPN-SAF Languages English French German Spanish Dutch Swedish Italian Portuguese Mandarin Japanese Hebrew MPN-SAF Languages English French German Spanish Dutch Swedish Italian Portuguese Mandarin Japanese Hebrew Slide 6 Quartile 1 (Q1): 0-24% Quartile 2 (Q2): 25-49% Quartile 3 (Q3): 50-74% Quartile 4 (Q4): 75- 100% Percentile MPN-SAF TSS Q1 TSS 32 ParameterP value of Comparison Age0.24 Gender F>M